Acute cardiac care & resuscitation
Mid-Term Survival in Patients Awaiting Heart and Kidney Transplantation with Impella 5.5 Support
Authors' conclusion
Our findings demonstrate that prolonged use of the Impella 5.5 provides safe and effective haemodynamic support for patients with end-stage heart and kidney failure awaiting dual-organ transplantation.
Study context
- Population
- Patients with end-stage HF and CKD listed for heart/kidney transplantation, bridged with Impella 5.5, Mayo Clinic Florida, December 2019–November 202210 underwent dual-organ transplantation (DOT)
- Participants
- 41 patients
- Outcome
- 1-year survival after DOT
- Follow-up
- 1 year
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
DOT
90%
Observational data: associations, not effects.
Further findings
| Outcome | Values |
|---|---|
| Haemodynamics after Impella placement | DOT RA pressure baseline 11 mmHg (7-16) · RA pressure post-Impella 5 mmHg (4-8) · SVO2 baseline 51 (46-61) · SVO2 post-Impella 70% (65-72) · Fick CI baseline 2.03 L/min/m² (1.66-2.5) · Fick CI post-Impella 5.5 (5.2-8) |
| Support and RRT | DOT Waitlist time, median 53 days (29-75) · Duration of Impella support, average 44 days (range 10-94) · RRT before DOT 8 of 10 · Total RRT duration, median 36 days (9-72) |
- Haemodynamics after Impella placement: RA P = 0.02
- Haemodynamics after Impella placement: SVO2 P = 0.002
- Haemodynamics after Impella placement: Fick CI P = 0.03
Transplantation success (all 41 patients)
- All patients underwent successful transplantation
- 41
Original publication
Mid-Term Survival in Patients Awaiting Heart and Kidney Transplantation with Impella 5.5 Support. ESC Heart Fail. Published 8 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →